BUSINESS
Mylan EPD Submits Clinical Trial Application in Japan for PIII Study of Eyedrop Therapy for Cystinosis
Mylan EPD said on September 24 that it has submitted a clinical trial application to the Pharmaceuticals and Medical Devices Agency (PMDA), aiming to start a PIII trial for A0003 (development code), an ophthalmic solution for the treatment of cystinosis,…
To read the full story
BUSINESS
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026
- Shionogi Closes US$2 Billion IntraBio Buyout, Gains Rare Disease Drug
November 19, 2026
- AbbVie Japan Launches Skyrizi 55 mg for Pediatric Psoriasis
November 19, 2026
- Japan Drug Makers’ H1 Sales Surge 14.7% as Weak Yen Fuels Growth
November 18, 2026
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…





